中国黑色素瘤患者对大剂量干扰素辅助治疗的耐受性观察.pdfVIP

2010 37 5 271 4 IFN-2b 2007 9 2009 5 29 AJCC b c IFN-2b 4 2 200 3 375U 5 2 4 NCI 2.0 29 17.63U/ m2 d 2 4 1 114 27 4 69% 20/29 3 4 62% 18/29 1 2 26 3 5 3 12 11IFN-2b doi:10.3969/j.issn.1000-8179.2010.05.009 ZHOU Qiang DING YaLI ChunyanPENG RuiqingZHANG Xing XIA Qing ZHANG Xiaoshi Corresponding author: ZHANG Xiaoshi, E-mail: zxs617@ State Key Laboratory of Oncology in South China, Biotherapy Research Center Sun Yat-sen University Cancer Center, Guangzhou 510060 China Grant support: Natural Science Foundation of Guangdong Province To observe the tolerability of Chinese melanoma patients to four-week high-dose interferon alfa-2b (INTRON A, Schering-Plough) therapy. A total of 29 patients with high risk melanoma [American Joint Committee on Cancer Staging (AJCC) IIB-IIIC] who received adjuvant interferon therapy in our hospital between September 2007 and May 2009 were retrospectively reviewed. Patients received 4 hours of intravenous infusion of interferon alfa-2b [dose range, 22.00 million international unit (MIU) to 33.75 MIU] IV 5 days/week for 4 weeks. The adverse events were evaluated with National Cancer Institute Common Toxicity Criteria (NCI 2.0 version). The average daily dose was 17.63 MIU/(m2 d). The therapy was ended in two patients because of poor wound healing or intolerability to severe fatigue. The most common adverse events were myelosuppression. Grade 3/4 neutropenia was observed in 69% (20/29) patients and was rapidly reversed after conventional support interve